Print | Email | Share | Comments (2)

Altea Partners With Amylin and Lilly to Develop 12-Hour Byetta Skin Patch

Apr 7, 2009

The patch, in a 12- and a 24-hour form, will use the company’s proprietary PassPort Transdermal Delivery System.

Buoyed by its recent successful phase 1 human clinical trial of a patch that delivers basal insulin through the skin, Atlanta-based Altea Therapeutics says it will work with Eli Lilly and Company and Amylin Pharmaceuticals, Inc., to develop a daily transdermal patch that deliver sustained levels of Byetta (exenatide). The patch, in a 12- and a 24-hour form, will use the company's proprietary PassPort Transdermal Delivery System. Lilly and Amylin will fund all development, manufacturing, and marketing activities for the product.

In its basal insulin patch study, Altea tested a 12-hour patch that delivered a steady therapeutic level of insulin to wearers. The company reported that its patch, which substituted for insulin injections, successfully provided sufficient and sustained doses. Because insulin therapy currently requires injections and needles, many patients are resistant to its use. Doctors and healthcare providers are hoping that the convenience and pain-free delivery offered by the insulin patch will encourage people with diabetes to begin insulin therapy sooner.

Similarly, Amylin and Lilly are hoping that Byetta, its injectable drug for controlling glucose and appetite, will achieve greater use and higher compliance rates if patients can take it in a non-injectable form. Although the drug is self-administered using pens with extremely short, thin needles that produce mild stings at worst, many people still shy away from the drug because of them.

Categories: Byetta, Diabetes, Diabetes, Insulin, Medications Research, Professional Issues

Comments

Posted by Anonymous on 14 April 2009

This form of treatment was on hold several years ago and now it's back. Are Pharmaceuticals panicking because stem cell treatment is just around the corner????

Posted by AllieB2 on 14 April 2009

I met the developers of Altea at an investors conference in 2006. At the time they were developing an insulin patch. Now that they've 'partnered' with Lilly - I wonder what became of the insulin idea. Was it a sell out for the Byetta deal? Thoughts, comments anybody?

Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Registered User Anonymous

Your Name:	Your Email:	X

Recipient's Name:	Recipient's Email:

Your Chosen Username:	Your Email Address:

Chosen Password:	Confirm Password:

Email to a Friend

Altea Partners With Amylin and Lilly to Develop 12-Hour Byetta Skin Patch

You May Also Be Interested In...

Comments

Register...

Have Your Say...

Diabetes Health

Topics

Topics

Topics

Diabetes Health Medical Disclaimer

Comment: